The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
As Tracky launches integrated health solution
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
